| abstract |
The present invention provides incretin analogues which are active against each of GIP, GLP-1, and a glucagon receptor. These insulinotropic analogues have structural features that produce balanced activity and prolong the duration of each of these receptors. Methods for treating diseases such as diabetes, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis, and obesity are also provided. |